Ultragenyx Pharmaceutical Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Emil D. Kakkis
- Full Time Employees
- 1,371
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 60 Leveroni Court Novato CA United States 94949
- IPO Date
- Jan 31, 2014
- CIK
- 0001515673
- Website
- ultragenyx.com
- Similar Companies
- Business
- Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare and ultrarare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company offers approved products including Crysvita (burosumab) for X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii for mucopolysaccharidosis VII; and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders; alongside a robust pipeline targeting conditions such as Angelman syndrome with GTX-102. Ultragenyx operates globally, with commercial presence in North America, Europe, and select international markets, serving patients through specialized support programs like UltraCare. In recent developments, Ultragenyx sold a portion of future North American royalties on Crysvita to OMERS Life Sciences for $400 million in November 2025; reported third quarter 2025 financial results with total revenue guidance of $640 million to $670 million; dosed the first patient in the Aurora study for GTX-102 in Angelman syndrome in October 2025; and appointed Eric Olson as Chief Business Officer in September 2025.
Company News
Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript
What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call
Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update
AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 7,066 Shares of Company Stock
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)
Analyzing Atara Biotherapeutics (NASDAQ:ATRA) & Ultragenyx Pharmaceutical (NASDAQ:RARE)
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE